The present invention relates to the technical field of microorganisms. Disclosed in the present invention are Lacticaseibacillus casei VB179 for inhibiting Malassezia, and a culture device and the use thereof. Specifically, disclosed in the present invention is Lacticaseibacillus casei VB179, wherein the Lacticaseibacillus casei VB179 is deposited in the China General Microbiological Culture Collection Center with a deposit number of CGMCC No. 28623 and a deposit date of 12 October 2023. The Lacticaseibacillus casei VB179 of the present invention can significantly inhibit the growth of Malassezia, and can further be used for treating skin diseases caused by the excessive reproduction of Malassezia, such as tinea versicolor, Malassezia folliculitis, seborrheic dermatitis and atopic dermatitis.
A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
The present invention relates to multiple polypeptides with high safety, cell repair capacity, and anti-inflammatory, hydrating and moisturizing effects, and the use thereof in cosmetics, wherein the amino acid sequences of the polypeptides are as set forth in SEQ ID NO: 1-SEQ ID NO: 6. The present invention also relates to a polynucleotide encoding the polypeptides, wherein the sequence of the polynucleotide is as set forth in SEQ ID NO: 7-SEQ ID NO: 12, and the sequence of the polynucleotide can be used for the detection of Deinococcus weizhi. In addition, further provided is a topical drug or a cosmetic, which contains any one of the polypeptides or a combination thereof as an active ingredient.
The present invention provides a novel microbial strain resource, specifically relates to the identification of Deinococcus Weizhi as a new species, and provides specific Deinococcus weizhi VB142 and Deinococcus weizhie VB226. A fermentation broth, a fermentation product filtrate, a fermentation lysate, and extracts of the fermentation broth can be obtained by means of conventional fermentation, are applicable for the preparation of antioxidant products, and have wide application value and market prospects.
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C12P 1/04 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes by using bacteria
A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
Provided are Akkermansia muciniphila VB202 and a use thereof. The strain was deposited at the China General Microbiological Culture Collection Center on 29 August 2023, with the accession number being CGMCC No. 28295. The provided Akkermansia muciniphila has relatively strong antibacterial ability, and can thus be used as an alternative to antibiotics; additionally, the strain has good hypoglycemic ability and intestinal tolerance, and can thus be used for preparing blood glucose control products.
Provided are lactobacillus delbrueckii subsp. bulgaricus VB183, and a culture apparatus and an application thereof, relating to the field of microorganisms. The accession number of the lactobacillus delbrueckii is CGMCC No. 28204. The lactobacillus delbrueckii of the present invention has advantages such as a high lactose degradation rate, strong beta-galactosidase activity, strong acid and alkali resistance, and strong bile salt resistance, has strong antibacterial ability against common pathogenic bacteria, can be used for relieving lactose intolerance, regulating intestinal flora, and preventing and treating intestinal diseases caused by pathogenic bacteria infection, and has a high application value. The provided lactobacillus delbrueckii subsp. bulgaricus VB183 culture apparatus can be used for batch producing lactobacillus delbrueckii subsp. bulgaricus VB183 fermentation products, which is beneficial for the development of microbial agents, foods, medicines, health care products or feed production apparatuses, and the batch production of commercial products, with a high economic value.
Provided are a lactobacillus reuteri VB319 and a culture apparatus and use therefor, relating to the field of microorganisms. The preservation number of the lactobacillus reuteri is CGMCC No.28158. The lactobacillus reuteri has the advantages of high lactose degradation rate, strong β-galactosidase activity, strong acid and alkali resistance, and strong cholate resistance etc., has strong antibacterial ability to common pathogenic bacteria, can be used for relieving lactose intolerance, regulating intestinal flora, and preventing and treating intestinal diseases caused by pathogenic bacteria infection. The application value is high. The lactobacillus reuteri VB319 culture apparatus can be used for batch producing fermentation products of the lactobacillus reuteri VB319, thereby facilitating the development of microbial agents, foods, medicines, health care products or feed production apparatuses. Commercial products can be produced in batches, and the economic value is high.
Provided are a bifidobacterium breve VB12 and a use thereof, relating to the field of microorganisms. The preservation number of the bifidobacterium breve is CGMCC No.28160. The bifidobacterium breve has the advantages of strong β-galactosidase activity, strong acid and alkali resistance, and strong cholate resistance etc., has strong bacteriostatic ability to common pathogenic bacteria, can be used for relieving lactose intolerance, regulating intestinal flora, and preventing and treating intestinal diseases caused by pathogenic bacteria infection.
Provided in the present invention are Streptococcus salivarius subsp.thermophilus VB331 and the use thereof. The strain is deposited at the China General Microbiological Culture Collection Center, with the deposit number of CGMCC NO.28407. The Streptococcus salivarius subsp.thermophilus can effectively inhibit the colonization, propagation and growth of various digestive tract pathogenic bacteria, including Escherichia coli, Staphylococcus aureus, Salmonella, Enterococcus faecalis, Listeria monocytogenes and Shigella, and especially has a strong inhibitory effect on Clostridium perfringens. The strain is a natural strain, is very safe, and can provide a new source of probiotics for the development of antibacterial, bacteriostatic and other functional products against multiple harmful bacterial infections.
A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
A23K 10/18 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
A23C 9/123 - Fermented milk preparationsTreatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceaeYoghurt
A23G 9/36 - Frozen sweets, e.g. ice confectionery, ice-creamMixtures therefor characterised by the composition containing microorganisms or enzymesFrozen sweets, e.g. ice confectionery, ice-creamMixtures therefor characterised by the composition containing paramedical or dietetical agents, e.g. vitamins
A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
Disclosed in the present invention is a Ligilactobacillus salivarius strain VB330, which is preserved in China General Microbiological Culture Collection Center on September 08, 2023, the accession number thereof being CGMCC No. 28406. The Ligilactobacillus salivarius VB330 disclosed by the present invention has broad-spectrum antibacterial characteristics, and has huge application prospects in the preparation of probiotic formulations, oral care products and drugs.
A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses
A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
Lactobacillus rhamnosus VB255 and a use thereof, the strain being deposited at the China General Microbiological Culture Collection Center on March 31, 2023 under the deposit number CGMCC NO. 26968. Lactobacillus rhamnosus VB255 has good stability, can stably exist in pancreatic juice without affecting the intestinal microecological environment, and has favorable inhibition effects against Candida albicans and/or Shigella.
The present invention relates to lactobacillus paracasei VB306 and a use thereof. The strain was preserved in China General Microbiological Culture Collection Center (CGMCC) on 24 July 2023, and has a preservation number of CGMCC No. 27999. The provided lactobacillus paracasei has a remarkable bile salt degradation capability, and can be used for preparing a drug for the degradation of cholesterol. Moreover, the strain has strong intestinal tolerance and antibacterial capability, and has a wide application prospect in the preparation of medications.
Disclosed in the present invention is Bifidobacterium animalis subsp.lactis VB315, which is deposited in China General Microbiological Culture Collection Center on August 14, 2023, with the deposit number of CGMCC No. 28159. The Bifidobacterium animalis subsp.lactis VB315 of the present invention has a significant ability to produce butyric acid, can be used in the preparation of a drug for maintaining intestinal health, has relatively strong antibacterial ability and anticholinergic ability, and has great application prospects with regard to the preparation of medicines.
Provided is Lactobacillus gasseri VB247, which was deposited at the China General Microbiological Culture Collection Center on 20 February 2023 with a deposit number of CGMCC No. 26575. The Lactobacillus gasseri VB247 can significantly improve the AQP2 mRNA expression level in female cervical and vaginal epithelial cells, and can be used for preventing and/or alleviating and/or treating vaginal lubrication disorders caused by perimenopause, premature ovarian failure, etc. In addition, the Lactobacillus gasseri VB247 has application prospects in the preparation of products such as foods, health-care foods, medicines, and hygiene products.
Disclosed in the present invention is Bifidobacterium animalis subsp. lactis VB301 and a use thereof. The strain is preserved in China General Microbiological Culture Collection Center on 24 July 2023, and has the preservation number of CGMCC No. 27998. The Bifidobacterium animalis subsp. lactis VB301 of the present invention has a remarkable bile salt reduction capability, can be used for preparing cholesterol-lowering drugs, has relatively strong intestinal tolerance and antibacterial capability, and has large prospects of application in the preparation of drugs.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
Provided is a Lactobacillus crispatus VB250, which is deposited in the China General Microbiological Culture Collection Center (CGMCC) on 20 February 2023, with the deposit number of CGMCC No.26574. The Lactobacillus crispatus provided in the present invention has good growth activity and multiple pathogenic bacteria inhibition activity in a low pH environment, and can be used for preventing and/or relieving and/or treating related diseases caused by vaginal flora disorder, such as bacterial vaginitis, colpitis mycotica, trichomonas vaginitis, aerobic vaginitis, senile vaginitis, and vaginitis caused by virus infection. Moreover, the Lactobacillus crispatus has great application prospects in preparation of products such as food, health-care food, drugs, and hygienic products.
The Lactobacillus plantarum VB165 strain, which was collected in the China General Microbiological Culture Collection Center on 28 September 2022 under preservation number CGMCC NO. 25839. When simulating in intestinal environment, the strain can inhibit the activity of α-glucosidase, can degrade bile salts, inhibits the activity of primary pathogenic gut bacteria, and possesses good tolerance to gastric acid and choline; said strain can be applied in the preparation of products to control blood glucose.
Provided is a Limosilactobacillus fermentum VB216, which has the deposit number of CGMCC No. 26578 in the China General Microbiological Culture Collection Center, and has the deposit date of 20 February 2023. The Limosilactobacillus fermentum has inhibitory activities with regard to a variety of pathogenic bacteria and excellent activity for degrading arginine. The present invention can be used in the preparation of products, such as food, health-care food, medicine and feed, for preventing and/or relieving and/or treating arginine metabolism-related diseases, such as hyperarginemia, malignant tumor treatment, allergic reactions, eczema, pruritus and abdominal spasm, and has great application prospects.
patents